Advances in the Knowledge of the Molecular Biology of Glioblastoma and Its Impact in Patient Diagnosis, Stratification, and Treatment

Достижения в изучении молекулярной биологии глиобластомы и их значение для диагностики, стратификации и лечения пациентов
Miguel Ángel Medina, Belén Delgado-Martín
2020-03-12

GlioblastomaMolecular biologyPatient stratificationSubtype-specific treatmentsTemozolomide
Gliomas are the most common primary brain tumors in adults. They arise in the glial tissue and primarily occur in the brain. Low-grade tumors of World Health Organization (WHO) grade II tend to progress to high-grade gliomas of WHO grade III and, eventually, glioblastoma of WHO grade IV, which is the most common and deadly glioma, with a median survival of 12-15 months after final diagnosis. Knowledge of the molecular biology and genetics of glioblastoma has increased significantly in the past few years, giving rise to classification methods that can help in management and stratification of glioblastoma patients. However, glioblastoma remains an incurable disease. Glioblastoma cells have acquired genetic and metabolic adaptations in order to sustain tumor growth and progression, including changes in energetic metabolism, invasive capacity, migration, and angiogenesis, that make it very difficult to find suitable therapeutic targets and to develop effective drugs. The current standard of care for glioblastoma patients is surgery followed by radiotherapy plus concomitant and adjuvant chemotherapy with temozolomide. Although progress in glioblastoma therapies in recent years has been more limited than in other tumors, numerous drugs and targets are being proposed and many clinical trials are underway to develop effective subtype-specific treatments.
1
Advances in glioblastoma molecular biology and genetics have enabled classification approaches supporting patient management and stratification.
2
Genetic and metabolic adaptations affecting energy metabolism, invasion, migration, and angiogenesis promote tumor progression and complicate therapeutic targeting.
3
Glioblastoma is the most common and lethal glioma, with a median survival of 12–15 months after final diagnosis.
4
Low-grade WHO grade II gliomas can progress to grade III tumors and eventually to WHO grade IV glioblastoma.
5
Numerous candidate drugs and molecular targets, including subtype-specific therapies, are being evaluated in ongoing clinical trials despite limited therapeutic progress.
6
The standard treatment is surgery followed by radiotherapy with concomitant and adjuvant temozolomide chemotherapy, but glioblastoma remains incurable.

glioblastoma

the molecular biology and genetics of glioblastoma and their implications for patient diagnosis, stratification, and treatment, including tumor growth, invasion, migration, angiogenesis, and therapeutic targeting

Publication Details
Publication Date
2020-03-12
Journal
Publisher
ISSN
Cited by
218
Access Type
Author Information
Authors
Miguel Ángel Medina
Belén Delgado-Martín
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%